67625-37-0

Basic information

• Product Name: Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate
• Synonyms: Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate;6-BroMo-iMidazo[1,2-a]pyridine-2-carboxylicacidethylesterhydrobroMide;6-Bromo-2-(ethoxycarbonyl)imidazo[1,2-a]pyridine;6-broMo-3-ethyliMidazo[1,2-a]pyridine-2-carboxylate;Ethyl6-bromoimidazo[1,2-a]pyridine-2-carboxylate98%;Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate 98%;ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate hydrobromide;Imidazo[1,2-a]pyridine-2-carboxylic acid, 6-bromo-, ethyl ester
• CAS NO: 67625-37-0
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.1
• Product Categories: blocks;Bromides;Imidazoles;Pyridines;Esters;Fused Ring Systems
• Mol File: 67625-37-0.mol
• Article Data: 15

Chemical Properties

• Melting Point: 69-72℃
• Appearance: /
• Density: 1.6 g/cm³
• Refractive Index: 1.637
• Storage Temp.: 2-8°C
• PKA: 1.58±0.50(Predicted)
• CAS DataBase Reference: Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate(67625-37-0)
• EPA Substance Registry System: Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate(67625-37-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 67625-37-0(Hazardous Substances Data)

Usage

General Description

Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate is a chemical compound with the molecular formula C10H8BrN3O2. It is a derivative of the imidazopyridine class of compounds and is commonly used in pharmaceutical research as a building block for the synthesis of potential drug candidates. Ethyl 6-bromoimidazo[1,2-a]pyridine-2-carboxylate is known for its potential biological activities and has been studied for its anti-inflammatory, anti-cancer, and antimicrobial properties. Its unique structure and reactivity make it a valuable tool for drug discovery and development, as well as for academic research in the field of medicinal chemistry.

InChI:InChI=1/C10H9BrN2O2/c1-2-15-10(14)8-6-13-5-7(11)3-4-9(13)12-8/h3-6H,2H2,1H3

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 1173694-07-9 6-(3-methoxyphenyl)-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 
• 1173694-01-3 6-phenylimidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 
• 1172362-03-6 C₁₆H₁₃FN₂O₂ 
• 1173694-05-7 6-(4-fluoro-3-methylphenyl)-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 
• 1171094-69-1 6-(4-methoxy-3,5-dimethylphenyl)-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 
• 1167055-21-1 ethyl 6-[3-(hydroxymethyl)phenyl]imidazo[1,2-a]pyridine-2-carboxylate 
• 1202701-43-6 (S)-ethyl 6-(4-(5-(acetamidomethyl)-2-oxooxazolidine-3-yl)-2-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxylate 
• 38922-77-9 ethyl 3-imidazo[1,2-a]pyridine-2-carboxylate 
• 885276-09-5 6-bromoimidazo[1,2-a]pyridine-2-carbaldehyde 
• 1167055-08-4 N-(3-cyano-5-fluorophenyl)-6-[3-(hydroxymethyl)phenyl]imidazo[1,2-a]pyridine-2-carboxamide 
• 1167055-24-4 6-[3-(Hydroxymethyl)phenyl]imidazo[1,2-a]pyridine-2-carboxylic acid 
• 1516888-13-3 4-((3-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-5-mercapto-4H-1,2,4-triazol-4-ylimino)methyl)phenol 

Relevant articles and documents

A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors

Utilizing modeling information from a recently resolved structure of human HIF-1α prolyl hydroxylase (EGLN1) and structure-based design, a novel series of imidazo[1,2-a]pyridine derivatives was prepared. The activity of these compounds was determined in a

HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS

The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.